Clinical Trials

Alabama Oncology considers clinical research to be an important part of our overall mission. We’re proud to provide access to cutting edge treatment options in your community, close to home.

If you think you might be interested in taking part in a clinical trial and would like to speak to someone for more information, please ask your physician or contact a clinical research coordinator at (205) 803-4389.

Alabama Oncology participates in a broad list of innovative studies that strive to advance medical science. Please see the current list of studies we have available for our patients below:

Treatment Studies:




NSCLC: AZ Latify: A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy




HER2+: Genentech WO42633: A phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of adjuvant atezolizumab or placebo and trastuzumab emtansine for her2-positive breast cancer at high risk of recurrence following preoperative therapy

TNBC: Gilead Ascent-05: Phase III Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05)

ER+ HER2 Early stage: AZ Cambria-1: A phase III open label randomized study to assess the efficacy and safety of switching to AZD9833 vs continuing standard endocrine therapy (aromatase inhibitor or tamoxifen) in Patients with HR+/HER2- early breast cancer and an intermediate or high risk of recurrence who have completed definitive locoregional therapy and at least 2 years of adjuvant endocrine therapy without disease recurrence.

Observational / Biomarker Studies:


Various Tumor types


Exact Science Ascend2: Multi cancer early detection (MCED) test development for tx naïve solid tumors. (1x Blood)

Freenome: MCED test development for all tx naïve cancer pts, OR pts w/ comorbidities. (1x Blood + pt survey)

Exact Sciences ES2021-05: MCED test development for newly dx or recurrent cancers. (1x Blood & tissue)



MT2432: NSCLC adenocarcinoma biomarker study EGFR/KRAS unk or + (1x Blood)
MT2450: NSCLC adenocarcinoma biomarker study EGFR/KRAS unk (closed) or + (1x Blood)
MT3805: NSCLC biomarker study (1x Blood)




MT3805: TNBC biomarker study (1x Blood)




MT0282: Biomarker study for mCRPC for pts starting a new qualifying line of tx (up to 3x blood draw visits)




Morphosys: R/R DLBCL (Registry+SAE monitoring + retrospective or prospective chart review)




BMS 6kx: Observational study for EJ/GEJ pts starting nivolumab (SAE monitoring+ Quarterly pt surveys)




GSK 219102: 1L maintenance Nirapirib therapy in advanced epithelial ovarian cancer (retrospective chart review)